Differential expression of tescalcin by modification of promoter methylation controls cell survival in gastric cancer cells

Kim,Tae   Woo; Han,Seung   Ro; Kim,Jong‑Tae; Yoo,Seung‑Min; Lee,Myung‑Shin; Lee,Seung‑Hoon; Kang,Yun   Hee; Lee,Hee   Gu

doi:10.3892/or.2019.7099

Differential expression of tescalcin by modification of promoter methylation controls cell survival in gastric cancer cells

Authors:
- Tae Woo Kim
- Seung Ro Han
- Jong‑Tae Kim
- Seung‑Min Yoo
- Myung‑Shin Lee
- Seung‑Hoon Lee
- Yun Hee Kang
- Hee Gu Lee
View Affiliations

Affiliations: Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34824, Republic of Korea, Eulji Biomedical Science Research Institute, Eulji University School of Medicine, Daejeon 34824, Republic of Korea
Published online on: April 4, 2019 https://doi.org/10.3892/or.2019.7099
Pages: 3464-3474

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The EF‑hand calcium binding protein tescalcin (TESC) is highly expressed in various human and mouse cancer tissues and is therefore considered a potential oncogene. However, the underlying mechanism that governs TESC expression remains unclear. Emerging evidence suggests that TESC expression is under epigenetic regulation. In the present study, the relationship between the epigenetic modification and gene expression of TESC in gastric cancer was investigated. To evaluate the relationship between the methylation and expression of TESC in gastric cancer, the methylation status of CpG sites in the TESC promoter was analyzed using microarray with the Illumina Human Methylation27 BeadChip (HumanMethylation27_270596_v.1.2), gene profiles from the NCBI Dataset that revealed demethylated status were acquired, and real‑time methylation‑specific PCR (MSP) in gastric cancer cells was conducted. In the present study, it was demonstrated that the hypermethylation of TESC led to the downregulation of TESC mRNA/protein expression. In addition, 5‑aza‑2c‑deoxycytidine (5'‑aza‑dC) restored TESC expression in the tested gastric cancer cells except for SNU‑620 cells. ChIP assay further revealed that the methylation of the TESC promoter was associated with methyl‑CpG binding domain protein (MBD)1, histone deacetylase (HDAC)2, and Oct‑1 and that treatment with 5'‑aza‑dC facilitated the dissociation of MBD1, HDAC2, and Oct‑1 from the promoter of TESC. Moreover, silencing of TESC increased MBD1 expression and decreased the H3K4me2/3 level, thereby causing transcriptional repression and suppression of cell survival in NCI‑N87 cells; conversely, overexpression of TESC downregulated MBD1 expression and upregulated the H3K4me2 level associated with active transcription in SNU‑638 cells. These results indicated that the differential expression of TESC via the modification status of the promoter and histone methylation controled cell survival in gastric cancer cells. Overall, the present study provided a novel therapeutic strategy for gastric cancer.

View Figures

View References

1	Takamatsu G, Katagiri C, Tomoyuki T, Shimizu-Okabe C, Nakamura W, Nakamura-Higa M, Hayakawa T, Wakabayashi S, Kondo T, Takayama C, et al: Tescalcin is a potential target of class Ihistone deacetylase inhibitors in neurons. Biochem Biophys Res Commun. 482:1327–1333. 2017. View Article : Google Scholar : PubMed/NCBI
2	Mailänder J, Müller-Esterl W and Dedio J: Human homolog of mouse tescalcin associates with Na⁺/H⁺ exchanger type-1. FEBS Lett. 507:331–335. 2001. View Article : Google Scholar : PubMed/NCBI
3	Malo ME and Fliegel L: Physiological role and regulation of the Na⁺/H⁺ exchanger. Can J Physiol Pharmacol. 84:1081–1095. 2006. View Article : Google Scholar : PubMed/NCBI
4	Loo SY, Chang MK, Chua CS, Kumar AP, Pervaiz S and Clement MV: NHE-1: A promising target for novel anti-cancer therapeutics. Curr Pharm Des. 18:1372–1382. 2012. View Article : Google Scholar : PubMed/NCBI
5	Fan J, Xing Y, Wen X, Jia R, Ni H, He J, Ding X, Pan H, Qian G, Ge S, et al: Long non-coding RNA ROR decoys gene-specific histone methylation to promote tumorigenesis. Genome Biol. 16:1392015. View Article : Google Scholar : PubMed/NCBI
6	Kang YH, Han SR, Kim JT, Lee SJ, Yeom YI, Min JK, Lee CH, Kim JW, Yoon SR, Yoon DY, et al: The EF-hand calcium-binding protein tescalcin is a potential oncotarget in colorectal cancer. Oncotarget. 5:2149–2160. 2014. View Article : Google Scholar : PubMed/NCBI
7	Kang J, Kang YH, Oh BM, Uhm TG, Park SY, Kim TW, Han SR, Lee SJ, Lee Y and Lee HG: Tescalcin expression contributes to invasive and metastatic activity in colorectal cancer. Tumour Biol. 37:13843–13853. 2016. View Article : Google Scholar : PubMed/NCBI
8	Levay K and Slepak VZ: Tescalcin is an essential factor in megakaryocytic differentiation associated with Ets family gene expression. J Clin Invest. 117:2672–2683. 2007. View Article : Google Scholar : PubMed/NCBI
9	Seth A, Ascione R, Fisher RJ, Mavrothalassitis GJ, Bhat NK and Papas TS: The ets gene family. Cell Growth Differ. 3:327–334. 1992.PubMed/NCBI
10	Wasylyk B, Hahn SL and Giovane A: The Ets family of transcription factors. Eur J Biochem. 211:7–18. 1993. View Article : Google Scholar : PubMed/NCBI
11	Oikawa T and Yamada T: Molecular biology of the Ets family of transcription factors. Gene. 303:11–34. 2003. View Article : Google Scholar : PubMed/NCBI
12	Seth A and Watson DK: ETS transcription factors and their emerging roles in human cancer. Eur J Cancer. 41:2462–2478. 2005. View Article : Google Scholar : PubMed/NCBI
13	Hogart A, Lichtenberg J, Ajay SS, Anderson S; NIH Intramural Sequencing Center, ; Margulies EH and Bodine DM: Genome-wide DNA methylation profiles in hematopoietic stem and progenitor cells reveal overrepresentation of ETS transcription factor binding sites. Genome Res. 22:1407–1418. 2012. View Article : Google Scholar : PubMed/NCBI
14	Schones DE and Zhao K: Genome-wide approaches to studying chromatin modifications. Nat Rev Genet. 9:179–191. 2008. View Article : Google Scholar : PubMed/NCBI
15	Liu B, Tahk S, Yee KM, Fan G and Shuai K: The ligase PIAS1 restricts natural regulatory T cell differentiation by epigenetic repression. Science. 330:521–525. 2010. View Article : Google Scholar : PubMed/NCBI
16	Ling ZQ, Tanaka A, Li P, Nakayama T, Fujiyama Y, Hattori T and Sugihara H: Microsatellite instability with promoter methylation and silencing of hMLH1 can regionally occur during progression of gastric carcinoma. Cancer Lett. 297:244–251. 2010. View Article : Google Scholar : PubMed/NCBI
17	Qu Y, Dang S and Hou P: Gene methylation in gastric cancer. Clin Chim Acta. 424:53–65. 2013. View Article : Google Scholar : PubMed/NCBI
18	Yamamoto E, Suzuki H, Takamaru H, Yamamoto H, Toyota M and Shinomura Y: Role of DNA methylation in the development of diffuse-type gastric cancer. Digestion. 83:241–249. 2011. View Article : Google Scholar : PubMed/NCBI
19	Yu JS, Koujak S, Nagase S, Li CM, Su T, Wang X, Keniry M, Memeo L, Rojtman A, Mansukhani M, et al: PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene. 27:4657–4665. 2008. View Article : Google Scholar : PubMed/NCBI
20	Ai L, Kim WJ, Kim TY, Fields CR, Massoll NA, Robertson KD and Brown KD: Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Cancer Res. 66:7899–7909. 2006. View Article : Google Scholar : PubMed/NCBI
21	Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tai HH, Karlan BY and Koeffler HP: 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res. 66:7818–7823. 2006. View Article : Google Scholar : PubMed/NCBI
22	Hendrich B and Tweedie S: The methyl-CpG binding domain and the evolving role of DNA methylation in animals. Trends Genet. 19:269–277. 2003. View Article : Google Scholar : PubMed/NCBI
23	Hendrich B and Bird A: Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol. 18:6538–6547. 1998. View Article : Google Scholar : PubMed/NCBI
24	Ballestar E and Esteller M: Methyl-CpG-binding proteins in cancer: Blaming the DNA methylation messenger. Biochem Cell Biol. 83:374–384. 2005. View Article : Google Scholar : PubMed/NCBI
25	Sansom OJ, Maddison K and Clarke AR: Mechanisms of disease: Methyl-binding domain proteins as potential therapeutic targets in cancer. Nat Clin Pract Oncol. 4:305–315. 2007. View Article : Google Scholar : PubMed/NCBI
26	Jørgensen HF, Ben-Porath I and Bird AP: Mbd1 is recruited to both methylated and nonmethylated CpGs via distinct DNA binding domains. Mol Cell Biol. 24:3387–3395. 2004. View Article : Google Scholar : PubMed/NCBI
27	Liu H, Jin G, Wang H, Wu W, Liu Y, Qian J, Fan W, Ma H, Miao R, Hu Z, et al: Methyl-CpG binding domain 1 gene polymorphisms and lung cancer risk in a Chinese population. Biomarkers. 13:607–617. 2008. View Article : Google Scholar : PubMed/NCBI
28	Wang J, Tai LS, Tzang CH, Fong WF, Guan XY and Yang M: 1p31, 7q21 and 18q21 chromosomal aberrations and candidate genes in acquired vinblastine resistance of human cervical carcinoma KB cells. Oncol Rep. 19:1155–1164. 2008.PubMed/NCBI
29	Monnier P, Martinet C, Pontis J, Stancheva I, Ait-Si-Ali S and Dandolo L: H19 lncRNA controls gene expression of the Imprinted Gene Network by recruiting MBD1. Proc Natl Acad Sci USA. 110:20693–20698. 2013. View Article : Google Scholar : PubMed/NCBI
30	Wang P, Lin C, Smith ER, Guo H, Sanderson BW, Wu M, Gogol M, Alexander T, Seidel C, Wiedemann LM, et al: Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol Cell Biol. 29:6074–6085. 2009. View Article : Google Scholar : PubMed/NCBI
31	Zheng YG, Wu J, Chen Z and Goodman M: Chemical regulation of epigenetic modifications: Opportunities for new cancer therapy. Med Res Rev. 28:645–687. 2008. View Article : Google Scholar : PubMed/NCBI
32	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
33	Gibney ER and Nolan CM: Epigenetics and gene expression. Heredity. 105:4–13. 2010. View Article : Google Scholar : PubMed/NCBI
34	Kulis M and Esteller M: DNA methylation and cancer. Adv Genet. 70:27–56. 2010. View Article : Google Scholar : PubMed/NCBI
35	Nile CJ, Read RC, Akil M, Duff GW and Wilson AG: Methylation status of a single CpG site in the IL6 promoter is related to IL6 messenger RNA levels and rheumatoid arthritis. Arthritis Rheum. 58:2686–2693. 2008. View Article : Google Scholar : PubMed/NCBI
36	Prokhortchouk E and Hendrich B: Methyl-CpG binding proteins and cancer: Are MeCpGs more important than MBDs? Oncogene. 21:5394–5399. 2002. View Article : Google Scholar : PubMed/NCBI
37	Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J and Wolffe AP: Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet. 19:187–191. 1998. View Article : Google Scholar : PubMed/NCBI
38	Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, Erdjument-Bromage H, Tempst P, Reinberg D and Bird A: MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet. 23:58–61. 1999. View Article : Google Scholar : PubMed/NCBI
39	Clark SJ, Harrison J and Molloy PL: Sp1 binding is inhibited by ^mCp^mCpG methylation. Gene. 195:67–71. 1997. View Article : Google Scholar : PubMed/NCBI
40	Kim TW, Lee SJ, Oh BM, Lee H, Uhm TG, Min JK, Park YJ, Yoon SR, Kim BY, Kim JW, et al: Epigenetic modification of TLR4 promotes activation of NF-κB by regulating methyl-CpG-binding domain protein 2 and Sp1 in gastric cancer. Oncotarget. 7:4195–4209. 2016.PubMed/NCBI
41	Murayama A, Sakura K, Nakama M, Yasuzawa-Tanaka K, Fujita E, Tateishi Y, Wang Y, Ushijima T, Baba T, Shibuya K, et al: A specific CpG site demethylation in the human interleukin 2 gene promoter is an epigenetic memory. EMBO J. 25:1081–1092. 2006. View Article : Google Scholar : PubMed/NCBI
42	Perera EM, Bao Y, Kos L and Berkovitz G: Structural and functional characterization of the mouse tescalcin promoter. Gene. 464:50–62. 2010. View Article : Google Scholar : PubMed/NCBI
43	Stein L, Rothschild J, Luce J, Cowell JK, Thomas G, Bogdanova TI, Tronko MD and Hawthorn L: Copy number and gene expression alterations in radiation-induced papillary thyroid carcinoma from chernobyl pediatric patients. Thyroid. 20:475–487. 2010. View Article : Google Scholar : PubMed/NCBI
44	Man CH, Lam SS, Sun MK, Chow HC, Gill H, Kwong YL and Leung AY: A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD⁺ AML. Blood. 123:2530–2539. 2014. View Article : Google Scholar : PubMed/NCBI
45	Qureshi SA, Bashir MU and Yaqinuddin A: Utility of DNA methylation markers for diagnosing cancer. Int J Surg. 8:194–198. 2010. View Article : Google Scholar : PubMed/NCBI
46	Kim TW, Kim B, Kim JH, Kang S, Park SB, Jeong G, Kang HS and Kim SJ: Nuclear-encoded mitochondrial MTO1 and MRPL41 are regulated in an opposite epigenetic mode based on estrogen receptor status in breast cancer. BMC Cancer. 13:5022013. View Article : Google Scholar : PubMed/NCBI
47	Chen B, Zeng C, Ye Y, Wu D, Mu Z, Liu J, Xie Y and Wu H: Promoter methylation of TCF21 may repress autophagy in the progression of lung cancer. J Cell Commun Signal. 12:423–432. 2018. View Article : Google Scholar : PubMed/NCBI
48	Wang Y, He T, Herman JG, Linghu E, Yang Y, Fuks F, Zhou F, Song L and Guo M: Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth. Clin Epigenetics. 9:1152017. View Article : Google Scholar : PubMed/NCBI
49	Solomon O, Yousefi P, Huen K, Gunier RB, Escudero-Fung M, Barcellos LF, Eskenazi B and Holland N: Prenatal phthalate exposure and altered patterns of DNA methylation in cord blood. Environ Mol Mutagen. 58:398–410. 2017. View Article : Google Scholar : PubMed/NCBI
50	Han KM, Won E, Kang J, Choi S, Kim A, Lee MS, Tae WS and Ham BJ: TESC gene-regulating genetic variant (rs7294919) affects hippocampal subfield volumes and parahippocampal cingulum white matter integrity in major depressive disorder. J Psychiatr Res. 93:20–29. 2017. View Article : Google Scholar : PubMed/NCBI
51	Delcuve GP, Khan DH and Davie JR: Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics. 4:52012. View Article : Google Scholar : PubMed/NCBI
52	Sarkar S, Abujamra AL, Loew JE, Forman LW, Perrine SP and Faller DV: Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling. Anticancer Res. 31:2723–2732. 2011.PubMed/NCBI
53	Campanero MR, Armstrong MI and Flemington EK: CpG methylation as a mechanism for the regulation of E2F activity. Proc Natl Acad Sci USA. 97:6481–6486. 2000. View Article : Google Scholar : PubMed/NCBI
54	Tian HP, Lun SM, Huang HJ, He R, Kong PZ, Wang QS, Li XQ and Feng YM: DNA methylation affects the SP1-regulated transcription of FOXF2 in breast cancer cells. J Biol Chem. 290:19173–19183. 2015. View Article : Google Scholar : PubMed/NCBI
55	Garrity PA, Chen D, Rothenberg EV and Wold BJ: Interleukin-2 transcription is regulated in vivo at the level of coordinated binding of both constitutive and regulated factors. Mol Cell Biol. 14:2159–2169. 1994. View Article : Google Scholar : PubMed/NCBI
56	Iguchi-Ariga SM and Schaffner W: CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. Genes Dev. 3:612–619. 1989. View Article : Google Scholar : PubMed/NCBI
57	Nair SS, Coolen MW, Stirzaker C, Song JZ, Statham AL, Strbenac D, Robinson MD and Clark SJ: Comparison of methyl-DNA immunoprecipitation (MeDIP) and methyl-CpG binding domain (MBD) protein capture for genome-wide DNA methylation analysis reveal CpG sequence coverage bias. Epigenetics. 6:34–44. 2011. View Article : Google Scholar : PubMed/NCBI
58	Fujita N, Takebayashi S, Okumura K, Kudo S, Chiba T, Saya H and Nakao M: Methylation-mediated transcriptional silencing in euchromatin by methyl-CpG binding protein MBD1 isoforms. Mol Cell Biol. 19:6415–6426. 1999. View Article : Google Scholar : PubMed/NCBI
59	Patra SK, Patra A, Zhao H, Carroll P and Dahiya R: Methyl-CpG-DNA binding proteins in human prostate cancer: expression of CXXC sequence containing MBD1 and repression of MBD2 and MeCP2. Biochem Biophys Res Commun. 302:759–766. 2003. View Article : Google Scholar : PubMed/NCBI
60	Bird AP and Wolffe AP: Methylation-induced repression-belts, braces, and chromatin. Cell. 99:451–454. 1999. View Article : Google Scholar : PubMed/NCBI
61	Dhasarathy A and Wade PA: The MBD protein family - reading an epigenetic mark? Mutat Res. 647:39–43. 2008. View Article : Google Scholar : PubMed/NCBI
62	Ng HH, Xu RM, Zhang Y and Struhl K: Ubiquitination of histone H2B by Rad6 is required for efficient Dot1-mediated methylation of histone H3 lysine 79. J Biol Chem. 277:34655–34657. 2002. View Article : Google Scholar : PubMed/NCBI
63	Fernandez-Capetillo O, Allis CD and Nussenzweig A: Phosphorylation of histone H2B at DNA double-strand breaks. J Exp Med. 199:1671–1677. 2004. View Article : Google Scholar : PubMed/NCBI
64	Tamagawa H, Oshima T, Shiozawa M, Morinaga S, Nakamura Y, Yoshihara M, Sakuma Y, Kameda Y, Akaike M, Masuda M, et al: The global histone modification pattern correlates with overall survival in metachronous liver metastasis of colorectal cancer. Oncol Rep. 27:637–642. 2012.PubMed/NCBI